Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia-Reference-Cited by-同舟云学术

Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia

Published:2018-07-19 Issue:8 Volume:33 Page:1381-1382
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Collins Michael¹

Affiliation:

1. Skeletal Disorders and Mineral Homeostasis Section; National Institute of Dental and Craniofacial Research; National Institutes of Health; Bethesda MD USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.3544/fullpdf

Reference10 articles.

1. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23;Nat Genet,2000

2. Fibroblast growth factor 23: state of the field and future directions;Bhattacharyya;Trends Endocrinol Metab,2012

3. Ruppe MD. 2012 Adam MP Ardinger HH Pagon RA https://www.ncbi.nlm.nih.gov/books/NBK83985/

4. A clinician's guide to X-linked hypophosphatemia;Carpenter;J Bone Miner Res,2011

5. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets;Francis;The HYP Consortium. Nat Genet,1995

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of oral health of patients with X-linked hypophosphatemia: case reports and literature review;BDJ Open;2024-05-31

2. Rare genetic skeletal disorders: Evolving terminology, therapies, education and advocacy;Journal of the Pediatric Orthopaedic Society of North America;2024-05

3. Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study;European Journal of Pediatrics;2023-09-14

4. Burosumab Improves Patient‐Reported Outcomes in Adults With Tumor‐Induced Osteomalacia: Mixed‐Methods Analysis;Journal of Bone and Mineral Research;2023-09-04

5. Burosumab: Current status and future prospects;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09